Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian Markets Pare Early Losses
Fri, 10 Apr 03:30 pm

Indian markets pared their losses and gained to close the session on a flattish note. BSE Sensex gained at least 75 points and is trading lower by about 5 points, while NSE-Nifty is marginally up by 2 points. BSE Mid Cap gained over 0.4% gains while BSE Small Cap garnered gains over 1%. Healthcare sector, which weighed on the Indian markets since morning gained positive momentum and is currently trading with a flattish tone. Metals and consumer durables have gained the most in today's trading session.

Commodities eroded morning losses and are trading with significant gains since mid-session. While the gold prices, per 10 grams, gained 0.7% or Rs 180; silver prices, per kilogram, gained 1.5% or Rs 550. Gold prices are trading near Rs 26,700 levels, while silver prices are trading near Rs 36,800 levels. Crude oil extended losses as it traded lower by 2% or Rs 70. Per barrel, crude oil is available at Rs 3,146 levels. The Dollar currency pared early gains and is trading slightly above by 0.14% or 0.09. The value of Indian Rupee stands at Rs 62.33 against the U.S Dollar.

The pharmaceutical sector stocks fell by about 1% today; however, they recouped towards the end. Sun Pharma, which had lost over 1% in the morning trade recovered all its losses by the end. Pharma major, Biocon received an approval from the Mexican health authority for Insulin Glargine. The company will partner PiSA Farmaceutica to market and sell Insulin Glargine as an affordable product for diabetes management. Following these developments shares of Biocon had gained as much as 1% in the morning session, but the gains were quickly eroded as the stock closed on a flat note.

" style="color:blue" target="_blank">Automobile sector managed to remain on the positive side of the trading session as it received mixed sales for the month of March from the data disclosed by the Society of Indian Automobile Manufacturers (SIAM). Domestic passenger sales group increased by 2.64% or 176,011 units in March compared to 171,491 units recorded last year, same month. On the negative side, sales of motorcycles fell over 5% to 859,521 units compared to 906,901 units recorded last year. Vehicles of all categories witnessed a slight decline of 0.15% from the month of March. However, on fiscal basis, vehicles sales registered a growth of over 7%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian Markets Pare Early Losses". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.